Today @ Colorado State has been replaced by SOURCE. This site exists as an archive of Today @ Colorado State stories between January 1, 2009 and September 8, 2014.

Veterinary Medicine

CSU spinoff VetDC raises $1.5 million to advance agent for canine lymphoma

December 3, 2012

CSU spinoff VetDC Inc. has announced the completion of a $1.5 million private financing, which will be used to advance VDC-1101 towards veterinary approval in canine lymphoma.

VDC-1101 is a novel targeted agent that has demonstrated substantial antitumor activity in pet dogs with lymphoma, and is anticipated to be one of the first FDA-approved drugs for the treatment of canine lymphoma.

One of first FDA-approved drugs

“This financing is a clear validation of the VetDC business concept and reinforces our belief that VDC-1101 represents a promising new treatment for canine lymphoma. VetDC is rapidly establishing itself as a leader in developing novel treatments for companion animals.”

“We are thrilled to secure this funding and initiate our VDC-1101 manufacturing campaign,” stated Steven Roy, VetDC’s President & CEO. “This financing is a clear validation of the VetDC business concept and reinforces our belief that VDC-1101 represents a promising new treatment for canine lymphoma. VetDC is rapidly establishing itself as a leader in developing novel treatments for companion animals.”

About VetDC Inc.

VetDC, a startup headquartered in Fort Collins, is a veterinary biotechnology company focused on in-licensing, developing and commercializing novel biotechnologies to address serious unmet medical needs in companion animals. In 2011, the company secured seed funding from the Colorado Institute for Drug, Device and Diagnostic Development (CID4).


Contact: Emily Wilmsen
E-mail: Emily.Wilmsen@colostate.edu
Phone: (970) 491-2336